To investigate the feasibility of SABR, investigators prospectively recruited 147 patients with oligometastatic cancer to the study. | Read More
Dan Brown, MD, shows case examples demonstrating timing of Y-90 therapy and personalizing therapy to the patient's biology. | Read More
Researchers have developed a prognostic score that can help to stratify candidates for transarterial chemoembolization (TACE), according to a study published in the Journal of Hepatology. | Read More
Patients with hepatocellular carcinoma and gross vascular invasion may have improved overall survival after being treated with dual modality radiation with external beam radiation therapy (EBRT) and transarterial radioembolization (TARE). | Read More
Results of a phase II trial suggest that image-guided high-dose-rate (HDR) brachytherapy (iBT) may lead to better outcomes than conventional transarterial embolization (cTACE) in treating unresectable hepatocellular carcinoma (HCC). | Read More

Spotlight

Dan Brown, MD, shows case examples demonstrating timing of Y-90 therapy and personalizing therapy to the patient's biology.
Because overall survival of patients with metastatic neuroendocrine tumors (NET) is usually longer than other types of metastatic cancers, deciding which treatment can best control the disease over a long period of time without causing long-term side effects that might affect survival or quality of life can be challenging, according to Dr Ghassan El-Haddad, Associate Member of Vascular and Interventional Radiology and Section Head of the Radionuclide Therapy Program at the Moffitt Cancer Center and Research Institute, University of South Florida.
In this video, Sean M. Tutton, MD, FSIR discusses the 5 P’s of MSK interventions and the importance of remembering the mnemonic device “Prior Planning Prevents Poor Performance.”